Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.
暂无分享,去创建一个
T. Yamanaka | Y. Tomizawa | K. Kubota | K. Fukuoka | M. Kawasaki | F. Ogushi | N. Nogami | H. Yoshioka | Y. Fujita | K. Asami | K. Shibata | K. Komuta | S. Atagi | T. Yonei | M. Kawahara | K. Minato | M. Tsuchiya
[1] Roman K. Thomas,et al. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[3] N. Ikeda,et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[5] S. Popat,et al. Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] A. Gemma,et al. F1000 highlights , 2010 .
[7] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[8] J. Crowley,et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Y. Nishiwaki,et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. , 2008, The Lancet. Oncology.
[10] N. Saijo,et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] W. M. Smit,et al. Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel , 2006, Clinical Cancer Research.
[12] M. Fujimura,et al. A phase II study of combination chemotherapy with docetaxel and carboplatin for patients with advanced or metastatic non-small cell lung cancer. , 2006, Anticancer research.
[13] H. Taniguchi,et al. Phase I/II Trial of Docetaxel and Carboplatin as a First-Line Therapy in Patients with Stage IV Non-Small-Cell Lung Cancer , 2006, Lung.
[14] J. Rigas. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. , 2004, The oncologist.
[15] M. Shibuya,et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Ramlau,et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Vasey. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] S. Clarke,et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[20] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[21] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[22] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.